Miller Howard Investments Inc. NY grew its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 0.3% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 488,004 shares of the company’s stock after purchasing an additional 1,333 shares during the quarter. Johnson & Johnson makes up approximately 2.9% of Miller Howard Investments Inc. NY’s holdings, making the stock its 2nd biggest position. Miller Howard Investments Inc. NY’s holdings in Johnson & Johnson were worth $80,774,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Atlantic Private Wealth LLC purchased a new stake in Johnson & Johnson in the 1st quarter worth approximately $32,000. Ruedi Wealth Management Inc. purchased a new stake in Johnson & Johnson in the 4th quarter worth approximately $42,000. 25 LLC purchased a new stake in Johnson & Johnson in the 1st quarter worth approximately $55,000. Horizons Wealth Management increased its holdings in Johnson & Johnson by 1,730.0% in the 2nd quarter. Horizons Wealth Management now owns 366 shares of the company’s stock worth $61,000 after acquiring an additional 346 shares in the last quarter. Finally, Bay Harbor Wealth Management LLC purchased a new stake in Johnson & Johnson in the 2nd quarter worth approximately $66,000. Hedge funds and other institutional investors own 68.40% of the company’s stock.
Analyst Ratings Changes
A number of equities research analysts have issued reports on the stock. Royal Bank of Canada assumed coverage on shares of Johnson & Johnson in a report on Wednesday, October 4th. They set an “outperform” rating and a $178.00 price objective for the company. TheStreet raised shares of Johnson & Johnson from a “c+” rating to a “b+” rating in a report on Monday, August 21st. Credit Suisse Group increased their price objective on shares of Johnson & Johnson from $170.00 to $175.00 and gave the company a “neutral” rating in a report on Friday, July 21st. Barclays cut their price objective on shares of Johnson & Johnson from $175.00 to $158.00 and set an “equal weight” rating for the company in a report on Friday, September 8th. Finally, Raymond James lowered their target price on Johnson & Johnson from $184.00 to $179.00 and set an “outperform” rating for the company in a research report on Tuesday, September 5th. Nine investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $171.06.
Johnson & Johnson Stock Down 0.1 %
Shares of JNJ opened at $158.35 on Wednesday. The firm has a market capitalization of $411.55 billion, a P/E ratio of 32.05, a P/E/G ratio of 3.19 and a beta of 0.55. Johnson & Johnson has a 12-month low of $150.11 and a 12-month high of $181.04. The company has a current ratio of 1.12, a quick ratio of 0.88 and a debt-to-equity ratio of 0.44. The firm has a fifty day moving average price of $163.91 and a 200-day moving average price of $162.50.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its earnings results on Thursday, July 20th. The company reported $2.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.62 by $0.18. The firm had revenue of $25.53 billion during the quarter, compared to analyst estimates of $24.63 billion. Johnson & Johnson had a net margin of 13.35% and a return on equity of 36.72%. The business’s revenue was up 6.3% on a year-over-year basis. During the same period in the previous year, the firm earned $2.59 earnings per share. Equities research analysts expect that Johnson & Johnson will post 10.02 earnings per share for the current year.
Johnson & Johnson Dividend Announcement
The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 7th. Investors of record on Monday, August 28th were issued a $1.19 dividend. The ex-dividend date was Friday, August 25th. This represents a $4.76 annualized dividend and a dividend yield of 3.01%. Johnson & Johnson’s payout ratio is currently 96.36%.
Insider Activity at Johnson & Johnson
In related news, VP Peter Fasolo sold 20,000 shares of Johnson & Johnson stock in a transaction dated Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total value of $3,406,400.00. Following the completion of the sale, the vice president now directly owns 102,696 shares in the company, valued at $17,491,182.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, insider William Hait sold 14,698 shares of Johnson & Johnson stock in a transaction dated Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total value of $2,528,056.00. Following the completion of the sale, the insider now directly owns 87,747 shares in the company, valued at $15,092,484. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Peter Fasolo sold 20,000 shares of Johnson & Johnson stock in a transaction dated Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total value of $3,406,400.00. Following the completion of the sale, the vice president now owns 102,696 shares of the company’s stock, valued at $17,491,182.72. The disclosure for this sale can be found here. 0.20% of the stock is currently owned by corporate insiders.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Read More
- Five stocks we like better than Johnson & Johnson
- 3 Small Caps With Big Return Potential
- 5 Reasons Gilead Sciences is a Better Buy Than You Think
- Consumer Staples Stocks, Explained
- Jobs Are Going To The Construction Industry, Momentum Play Time
- The 3 Best Fintech Stocks to Buy Now
- PepsiCo Q3 Strength Results In A Trend Following Buy Signal
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
